Report Description Table of Contents How Are Repeat Diabetes Testing, Point-of-Care Expansion, and Laboratory Competition Shaping the Global HbA1c Testing Devices Market? – (Updated On: 31st-Oct-2026) According to Strategic Market Research, the Global HbA1c Testing Devices Market was valued at USD 2.01 billion in 2025 and is projected to reach USD 3.24 billion by 2032, expanding at a CAGR of 7.1% during 2026–2032. The projected USD 1.23 billion increase in annual market revenue is supported by recurring diabetes monitoring, expanding screening coverage, and increasing adoption of laboratory and point-of-care HbA1c testing systems. Diabetes prevalence creates distinct opportunities in repeat monitoring and screening. WHO estimates that 830 million people worldwide were living with diabetes in 2022. In the United States, CDC estimates 40.1 million people had diabetes in 2023, comprising 29.1 million diagnosed individuals and 11.0 million undiagnosed adults. A further 115.2 million adults had prediabetes. Diagnosed patients support ongoing HbA1c monitoring, while undiagnosed diabetes and prediabetes populations represent potential demand for diagnosis and periodic assessment. World Health Organization Testing frequency makes consumables central to market revenue. CDC recommends HbA1c testing twice annually for patients meeting treatment goals and every three months when treatment changes or blood glucose goals are unmet. These repeat testing requirements support continuing purchases of reagents and cartridges. CDC Strategic Market Research estimates that reagents, cartridges, analytical columns, and other consumables accounted for 88.26% of market revenue in 2025, making sustained testing activity more commercially significant than analyzer sales alone. Medicare claims demonstrate substantial paid demand for HbA1c testing. In 2024, Medicare Part B recorded 18,998,926 HbA1c claim lines under procedure code 83036, generating USD 181.6 million in laboratory reimbursement; both volume and spending increased approximately 3% from 2023. This activity provides direct evidence of ongoing assay consumption within a major reimbursed testing channel. oig.hhs.gov Since January 1, 2024, Medicare has also included HbA1c within its diabetes-screening benefit, allowing eligible beneficiaries covered diabetes screening up to twice within the applicable 12-month period. This extends the reimbursed opportunity beyond monitoring established diabetes. cms.gov Point-of-care systems bring HbA1c testing into routine consultations. Abbott’s Afinion 2 and Siemens Healthineers’ DCA Vantage enable testing in physician offices and clinics, supporting treatment decisions during patient visits. Abbott’s Afinion HbA1c Dx assay also holds FDA clearance to aid diabetes diagnosis and identify at-risk patients. For manufacturers, these settings offer opportunities to pair analyzer placements with recurring cartridge purchases. Abbott MediaRoom Recent developments are widening laboratory competition and testing access. Lifotronic’s H100Plus Hemoglobin Testing System received FDA clearance on October 2, 2026, expanding its access to U.S. laboratory customers. In July 2026, Siemens Healthineers announced CE-marked capillary testing claims for Atellica analyzers, including HbA1c, broadening sample-collection options in applicable markets. These developments give laboratories additional choices when evaluating HbA1c systems and expanding testing services. The Global HbA1c Testing Devices Market is expected to expand through increasing testing frequency, broader diagnostic access, and continued investment in laboratory and point-of-care testing through 2032. Centralized laboratories will remain important purchasers of automated analyzers and consumables, while primary-care practices, diabetes clinics, and community health facilities offer additional opportunities for cartridge-based testing. Manufacturers with established distribution networks, reliable assay performance, competitive pricing, and strong technical support will be positioned to capture recurring revenue as diabetes monitoring and screening activity expands worldwide. Which Subsegments Are Leading the HbA1c Testing Devices Market, and Where Are the Strongest Commercial Opportunities Emerging? By Product: Reagents and Consumables Lead Market Revenue Leading and Fastest-Growing Subsegment – Reagents, Consumables and Home-Testing Kits: This category accounted for approximately 88.26% of global market revenue in 2025, valued at USD 1,774.00 million, and is projected to expand at a 7.40% CAGR through 2032. Its leadership reflects recurring purchasing requirements across laboratory analyzers, point-of-care devices, and dedicated home-testing products. Manufacturers benefit from continuing reagent and cartridge consumption after equipment adoption, making assay utilization and long-term customer relationships important revenue drivers. By Testing Setting: Laboratories Lead, While Point-of-Care Testing Expands Faster Leading Subsegment – Laboratory Testing: Laboratory testing represented 59.40% of the market, valued at USD 1,194.00 million in 2025, and is projected to expand at a 4.31% CAGR through 2032. Centralized laboratories maintain substantial testing volumes through hospital networks, independent diagnostic providers, and referral services. Their purchasing priorities include dependable assay supply, high-throughput processing, and predictable testing expenditure. Fastest-Growing Subsegment – Professional Point-of-Care Testing: Professional point-of-care testing accounted for 38.61% of market revenue, equivalent to USD 776.00 million in 2025, and is projected to expand at a 10.49% CAGR through 2032. Its growth reflects increasing demand for HbA1c testing during consultations, allowing healthcare providers to review results and discuss diabetes management within the same appointment. This creates recurring cartridge revenue opportunities for manufacturers serving outpatient and community-care facilities. By Technology: Ion-Exchange Chromatography Leads, While Enzymatic Methods Expand Fastest Leading Subsegment – Ion-Exchange Chromatography: Ion-exchange chromatography accounted for 29.89% of the global market, valued at USD 600.88 million in 2025, and is projected to expand at a 3.13% CAGR through 2032. Its commercial position reflects established use in dedicated laboratory analyzers, particularly among facilities requiring standardized HbA1c testing and recurring analytical-column purchases. Fastest-Growing Subsegment – Enzymatic Methods: Enzymatic methods represented 11.46% of market revenue, equivalent to USD 230.44 million in 2025, and are projected to record a 10.21% CAGR through 2032. Their growth is associated with the adoption of HbA1c assays on multipurpose clinical chemistry analyzers, allowing laboratories to expand test menus and increase assay consumption within established laboratory operations. By Application: Diabetes Monitoring Leads, While Prediabetes Monitoring Expands Fastest Leading Subsegment – Diabetes Monitoring: Diabetes monitoring accounted for 76.36% of global market revenue, valued at USD 1,534.80 million in 2025, and is projected to grow at a 6.41% CAGR through 2032. Repeat testing among diagnosed patients provides an established purchasing cycle for laboratories, hospitals, and diabetes clinics. Continued monitoring of treatment response supports predictable reagent and cartridge demand. Fastest-Growing Subsegment – Prediabetes Monitoring: Prediabetes monitoring represented 7.87% of the market, equivalent to USD 158.20 million in 2025, and is projected to expand at an 11.23% CAGR through 2032. Its growth reflects increasing attention to early diabetes risk identification and periodic follow-up. Primary-care networks and prevention programs provide opportunities for diagnostic manufacturers as testing access expands. By End User: Hospitals Lead Expenditure, While Pharmacies Expand Fastest Leading Subsegment – Hospitals: Hospitals accounted for 38.61% of the market, valued at USD 776.08 million in 2025, and are projected to expand at a 4.42% CAGR through 2032. Their demand includes central laboratory testing, outpatient diabetes monitoring, and specialized clinical services. Long-term laboratory contracts and assay replenishment support recurring manufacturer revenue. Fastest-Growing Subsegment – Pharmacies: Pharmacies represented 1.93% of market revenue, equivalent to USD 38.80 million in 2025, and are projected to record a 15.93% CAGR through 2032. Professional pharmacy-based HbA1c testing offers an additional access channel in markets where regulations permit such services. Commercial growth depends on service authorization, trained personnel, reimbursement, and patient participation. By Geography: North America Leads, While Asia Pacific Records the Fastest Growth Leading Region – North America: North America accounted for 35.43% of global market revenue, equivalent to USD 712.12 million in 2025, and is projected to expand at a 5.82% CAGR through 2032. Established laboratory infrastructure, substantial diagnosed diabetes populations, and reimbursed testing pathways support the region's commercial leadership. Fastest-Growing Region – Asia Pacific: Asia Pacific accounted for 24.72% of the global HbA1c Testing Devices Market, representing USD 496.90 million in 2025 revenue, and is projected to record the fastest regional 10.15% CAGR during 2026–2032. Increasing diabetes testing access, expansion of clinical laboratory networks, and adoption of professional point-of-care systems are supporting regional growth. China, Japan, Australia, and South Korea represent important commercial markets, with opportunities across automated laboratory testing, outpatient diabetes monitoring, and recurring reagent consumption. What Are the Key Applications of HbA1c Testing Devices Across Healthcare? Diabetes Monitoring and Long-Term Patient Management Diabetes monitoring represents the largest commercial application of HbA1c testing devices, supported by repeat testing among diagnosed patients. According to the National Institute of Diabetes and Digestive and Kidney Diseases, people with diabetes generally undergo HbA1c testing at least twice annually, with more frequent assessment when treatment goals require closer monitoring. This creates recurring demand for laboratory reagents, point-of-care cartridges, and analytical consumables. Hospitals, diagnostic laboratories, and specialist diabetes clinics represent established purchasing channels, while manufacturers benefit from sustained assay utilization and long-term supply contracts. Diabetes Screening and Diagnosis HbA1c testing supports diabetes identification among eligible individuals and provides an entry point into continuing care. The CDC's National Diabetes Statistics Report estimates that 11.0 million U.S. adults had undiagnosed diabetes in 2023, indicating a substantial population potentially requiring diagnostic assessment. Medicare's expansion of HbA1c screening coverage from January 2024 provides an additional reimbursement pathway for eligible patients. Commercial opportunities extend to clinical laboratories, primary-care providers, and professional testing facilities that serve screening populations. Prediabetes Monitoring and Preventive Healthcare Prediabetes monitoring creates opportunities for periodic testing through primary-care and diabetes-prevention services. The CDC estimates that 115.2 million U.S. adults had prediabetes in 2023, representing a substantial population potentially eligible for follow-up assessment. Actual testing demand depends on clinical eligibility, screening participation, and reassessment frequency. Manufacturers serving community healthcare networks can benefit from increasing use of professional testing systems and recurring assay purchases as preventive care expands. Point-of-Care Testing During Clinical Consultations Professional point-of-care HbA1c testing allows healthcare providers to assess glycemic control during patient appointments. Abbott's Afinion HbA1c system provides results in approximately three minutes, supporting testing during routine diabetes consultations. These systems are commercially relevant to primary-care practices, endocrinology clinics, and outpatient facilities seeking to combine testing with treatment review. Their recurring revenue potential comes from single-use cartridges and continued testing activity. Home-Based HbA1c Monitoring Dedicated home-testing products represent a smaller but expanding application. PTS Diagnostics' A1CNow Self Check offers five-minute results through a four-test package, supporting consumer access to periodic HbA1c assessment. The commercial opportunity depends on retail distribution, consumer purchasing frequency, product affordability, and integration with professional diabetes care. Home-testing kits create a distinct sales channel alongside laboratory and professional point-of-care products. Which Market Drivers Are Expanding HbA1c Testing Expenditure? Large Diagnosed Diabetes Populations Support Recurring Assay Demand The International Diabetes Federation's Diabetes Atlas estimates that approximately 588.7 million adults aged 20–79 were living with diabetes globally in 2024, including 251.7 million undiagnosed adults. This implies approximately 337 million diagnosed adults within the IDF population estimate. Diagnosed patients represent a substantial potential source of repeat HbA1c testing, while undiagnosed individuals create opportunities for screening and subsequent monitoring. For manufacturers, commercial demand depends on the proportion of patients receiving testing, annual testing frequency, and the diagnostic channel used. Screening Reimbursement Supports Greater Testing Access The Centers for Medicare & Medicaid Services expanded Medicare diabetes-screening coverage to include HbA1c testing effective January 1, 2024. Eligible beneficiaries can receive covered screening up to twice within the applicable 12-month period. This policy strengthens the financial pathway for testing among eligible at-risk populations and creates opportunities for laboratories and physician practices. Diagnostic manufacturers can benefit through higher assay consumption as reimbursed screening activity develops. Laboratory Testing Volumes Strengthen Recurring Consumable Sales According to the HHS Office of Inspector General, Medicare recorded approximately 19.0 million HbA1c laboratory claim lines in 2024, with USD 181.6 million in associated spending. These figures demonstrate the scale of recurring reimbursed testing activity within one major healthcare channel. Laboratory manufacturers compete for this demand through analyzer performance, reagent supply, service agreements, and competitive testing economics. Multipurpose Laboratory Platforms Support Additional HbA1c Assay Adoption Clinical laboratories increasingly have opportunities to conduct HbA1c testing alongside broader diagnostic services. Roche Diagnostics specifies HbA1c throughput of up to 500 samples per hour for its cobas c 503 analytical unit. Such capacity supports centralized laboratory testing and consolidation of diagnostic workflows. For manufacturers, the commercial opportunity includes recurring reagent sales and stronger customer relationships across broader laboratory portfolios. Which Trends Are Changing HbA1c Testing Access and Revenue Mix? Capillary Sample Collection Is Expanding Into Centralized Laboratories In July 2026, Siemens Healthineers announced 24 CE-marked capillary testing claims, including HbA1c, for Atellica laboratory analyzers. The development expands sample-collection options while retaining centralized laboratory processing. At the time of the announcement, four other capillary assays were identified for U.S. availability. This illustrates the importance of country-specific regulatory authorization in determining the commercial reach of expanded testing menus. Professional Point-of-Care Platforms Are Supporting Higher Clinic Testing Capacity Professional HbA1c testing systems are expanding the ability of outpatient facilities to conduct testing during consultations. Siemens Healthineers' Atellica DCA supports up to three testing modules connected to one display, allowing clinics to align testing capacity with patient demand. The manufacturer's product information identifies country-specific availability, including restrictions on U.S. sales. Commercial opportunities depend on regional approvals, appointment volumes, cartridge utilization, and healthcare-provider adoption. Consumer Testing Kits Are Creating Additional Distribution Opportunities Home-based HbA1c testing provides an additional channel for manufacturers serving consumers who purchase dedicated self-testing products. PTS Diagnostics offers its A1CNow Self Check in a four-test package, with results available in approximately five minutes. This format creates opportunities through pharmacies, retail distribution, and repeat consumer purchases. Commercial performance depends on product affordability, consumer awareness, and the role of self-testing within professional diabetes management. Laboratory Quality Requirements Are Increasing the Importance of Reliable Assay Supply Assay quality and manufacturer responsiveness influence laboratory purchasing and long-term customer relationships. A June 2026 FDA-listed correction involving Siemens Atellica enzymatic HbA1c reagents identified 24,077 affected assay-product units in commerce and additional quality-control actions. The event highlights the commercial importance of reliable test performance, effective customer communication, and responsive technical support in maintaining laboratory contracts and consumable purchasing continuity. Which Regions and Countries Offer Distinct Commercial Opportunities? North America: Established Diabetes Care Supports Recurring Testing Demand North America represents the largest regional market, supported by established diagnostic infrastructure, reimbursement systems, and continuing diabetes monitoring. According to the CDC, approximately 29.1 million people in the United States had diagnosed diabetes in 2023. This population supports ongoing laboratory and clinic-based HbA1c testing. Manufacturers compete through dependable reagent supply, analyzer performance, service coverage, and long-term agreements with health systems and physician practices. Europe: Documented Testing Coverage Supports Mature Laboratory Demand Europe benefits from structured diabetes care pathways and established laboratory testing networks. The NHS National Diabetes Audit recorded HbA1c measurement for 91.9% of England's audited type 2 and other diabetes population during 2024–2025. This indicates substantial documented testing coverage within a mature healthcare system. Manufacturers serving European laboratories can compete through efficient assay processing, predictable consumable costs, and reliable supply contracts. Asia Pacific: Broader Testing Access Supports Faster Market Expansion Asia Pacific presents opportunities through expanding diabetes services, laboratory capacity, and professional testing adoption. According to the Australian Institute of Health and Welfare, 74.9% of regular general-practice clients with type 2 diabetes had an HbA1c result recorded within the previous 12 months as of July 2026, compared with 60.0% of clients with type 1 diabetes. These figures describe recorded testing within participating general practices and indicate the importance of follow-up coverage and clinical documentation. Regional manufacturers and distributors can target laboratories, primary-care networks, and specialist clinics as testing access expands. Latin America: Brazil Offers Monitoring and Screening Opportunities Brazil represents an important Latin American market because of its substantial diabetes population. The International Diabetes Federation estimates approximately 16.6 million adults with diabetes in Brazil in 2024, with 31.9% remaining undiagnosed. This creates demand potential across established monitoring services and diagnostic screening. Manufacturers can pursue opportunities through laboratory distribution, primary-care testing, and competitive consumable pricing, with commercial adoption influenced by healthcare access and purchasing capacity. Middle East and Africa: Expanding Diabetes Services Support Diagnostic Investment The Middle East and Africa region offers opportunities through hospital laboratory development, specialist diabetes services, and community healthcare expansion. According to the International Diabetes Federation, Saudi Arabia had approximately 5.34 million adults living with diabetes in 2024. This population supports recurring monitoring demand across hospitals, specialist clinics, and outpatient facilities. Manufacturers seeking regional expansion must assess country-specific reimbursement arrangements, diagnostic access, distributor capabilities, and laboratory purchasing practices. Which Companies Are Shaping the Competitive Landscape of the Global HbA1c Testing Devices Market? Bio-Rad Laboratories — Major Supplier of Dedicated Laboratory HbA1c Testing Systems Bio-Rad Laboratories maintains a significant position in dedicated laboratory HbA1c testing through its D-100 Hemoglobin Testing System and associated analytical consumables. The company's portfolio supports high-volume laboratory testing, making instrument utilization and recurring reagent purchases central to its commercial offering. According to Bio-Rad Laboratories, the D-100 Hemoglobin Testing System delivers approximately 80 results per hour and uses a 10,000-test analytical column. These specifications demonstrate the commercial relationship between laboratory equipment adoption and continuing purchases of columns, buffers, calibrators, and other consumables. Bio-Rad's position in dedicated laboratory testing supports competition for hospital and independent diagnostic laboratory accounts requiring standardized HbA1c analysis and dependable long-term supply. Tosoh Bioscience — Established Laboratory Manufacturer Expanding Its HbA1c Analyzer Portfolio Tosoh Bioscience participates in the HbA1c Testing Devices Market through dedicated HPLC analyzers and recurring laboratory consumables. Its portfolio serves laboratories with varying testing requirements, allowing the company to compete through analyzer capacity, assay performance, and continuing reagent sales. On October 3, 2025, the U.S. FDA cleared Tosoh's HLC-723GR01 Automated Glycohemoglobin Analyzer under clearance number K250073. The system supports approximately 50-second analysis time, strengthening the company's laboratory testing portfolio. This regulatory clearance expands Tosoh's ability to compete for U.S. diagnostic laboratory accounts, while recurring purchases of analytical columns and reagents provide additional commercial opportunities following equipment adoption. Other Important Companies and Their Market Roles: Abbott: Supplies Afinion HbA1c point-of-care testing products, supporting consultation-based testing through dedicated analyzers and single-use cartridges. Roche Diagnostics: Provides HbA1c assays through cobas laboratory platforms and cobas b 101 systems, serving centralized laboratories and decentralized testing facilities. Siemens Healthineers: Offers DCA point-of-care testing systems and HbA1c assays for laboratory analyzers, addressing professional testing and centralized laboratory demand. ARKRAY: Supplies ADAMS A1c laboratory analyzers, including the HA-8190V, which processes samples in 24 seconds in fast mode and 58 seconds in variant mode, supporting different laboratory workloads. EKF Diagnostics: Provides Quo-Test HbA1c systems for diabetes clinics and physician practices, supporting professional cartridge-based testing. PTS Diagnostics: Offers A1CNow products for professional testing and dedicated consumer self-testing, addressing clinical and retail distribution channels. HemoCue: Supplies the HbA1c 501 system, providing results in approximately five minutes for decentralized diabetes monitoring services. Lifotronic: Expands laboratory competition through its FDA-cleared H100Plus Hemoglobin Testing System, supporting HbA1c analysis in approximately 45 seconds. Which Recent Product Developments and Regulatory Requirements Are Shaping Future Competition? Lifotronic's 2026 FDA Clearance Expands U.S. Laboratory Competition On October 2, 2026, the U.S. FDA cleared Lifotronic's H100Plus Hemoglobin Testing System under K260468. According to Lifotronic's October 2026 announcement, the system supports HbA1c analysis in approximately 45 seconds. The clearance creates an additional competitive opportunity in the U.S. laboratory market. Commercial adoption will depend on distribution agreements, laboratory validation, service support, and recurring assay purchasing. Tosoh's 2026 Analyzer Launch Provides a Measurable Commercial Sales Target On May 14, 2026, Tosoh launched the HLC-723GX2 in Japan, reducing analysis time from 2.2 minutes to 1.6 minutes per sample. The company projects sales of more than 2,000 units domestically and internationally during the first five years. This manufacturer target indicates planned commercialization activity and potential future demand for associated analytical consumables. Actual sales performance will depend on laboratory adoption, distributor reach, pricing, and product availability. Siemens' Capillary Testing Expansion Creates Additional Laboratory Opportunities In July 2026, Siemens Healthineers announced 24 CE-marked capillary testing claims, including HbA1c, for its Atellica laboratory analyzers. The development supports expanded sample-collection options within centralized laboratory testing. Future commercial opportunities depend on additional regulatory authorizations, assay availability, and adoption by laboratories seeking more flexible sample-collection pathways. FDA Quality-Control Actions Reinforce the Importance of Assay Reliability A June 2026 FDA-listed correction concerning Siemens Atellica enzymatic HbA1c reagents identified 24,077 affected assay-product units in commerce. The action involved additional quality-control requirements following concerns about potentially elevated or depressed results. This development reinforces the importance of product quality, responsive manufacturer support, and effective laboratory communication in maintaining customer confidence and recurring consumable revenue. Analyst Commentary: Where Will Manufacturers Capture Greater Commercial Value in the HbA1c Testing Devices Market? The global HbA1c Testing Devices Market presents its strongest commercial opportunities in recurring reagent and cartridge sales, expanding professional point-of-care testing, and improving utilization of laboratory analyzers. With consumables accounting for approximately 88.26% of estimated 2025 market revenue, manufacturers can strengthen long-term revenue through sustained testing activity, dependable assay supply, and laboratory partnerships. Professional point-of-care testing, projected to grow at a 10.49% CAGR through 2032, offers attractive expansion opportunities across primary-care practices, diabetes clinics, and community health facilities. We expect competitive advantage to increasingly depend on cost per test, regulatory approvals, assay reliability, distribution reach, and customer retention. Manufacturers that successfully convert growing diabetes screening and monitoring demand into repeat testing volumes will be positioned to capture a greater share of market growth through 2032. HbA1c Testing Devices Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 2.01 Billion Revenue Forecast in 2032 USD 3.24 Billion Overall Growth Rate CAGR of 7.1% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million/Billion, CAGR (2026 – 2032) Segmentation By Product, By Testing Setting, By Technology, By Application, By End User, By Geography By Product Reagents, Consumables and Home-Testing Kits, Instruments By Testing Setting Laboratory Testing, Professional Point-of-Care Testing, Home-Use Testing By Technology Ion-Exchange Chromatography, Immunoassay, Boronate-Affinity Methods, Enzymatic Methods, Capillary Electrophoresis, Other Methods By Application Diabetes Monitoring, Diabetes Screening and Diagnosis, Prediabetes Monitoring By End User Hospitals, Independent Diagnostic Laboratories, Primary Care and Community Health Centers, Diabetes and Endocrinology Clinics, Home Users, Pharmacies, Other End Users By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Recurring HbA1c monitoring requirements, expansion of diabetes and prediabetes screening, reimbursement coverage for eligible testing, adoption of point-of-care systems, continuing purchases of reagents and testing consumables Customization Option Available upon request Frequently Asked Question About This Report Q1. Why does repeat testing play such an important role in market growth? A1. Ongoing diabetes monitoring creates repeat purchases of reagents and cartridges after an analyzer is placed. Diabetes monitoring accounts for an estimated 76.36% revenue share in 2025. For manufacturers, regular test volumes support recurring sales and long-term supply relationships with healthcare providers. Q2. Which product categories generate the most revenue in the market? A2. Reagents, consumables and home-testing kits collectively account for an estimated 88.26% revenue share in 2025. Their dominance reflects repeated use across laboratory and point-of-care systems. Analyzer placements create the testing capacity while ongoing assay consumption generates most of the revenue. Q3. How is testing during patient consultations changing the industry? A3. Professional point-of-care systems allow providers to review results during the same appointment. This expands opportunities in primary-care practices and diabetes clinics. The segment is projected to grow at a CAGR of 10.49% during 2026–2032 through additional device placements and recurring cartridge purchases. Q4. What technology developments are creating opportunities in the market? A4. Enzymatic assays allow laboratories to add testing to multipurpose clinical chemistry platforms. This gives manufacturers opportunities to increase reagent sales within existing laboratory operations. Enzymatic methods are projected to be the fastest-growing technology segment at a CAGR of 10.21% during 2026–2032. Q5. Which emerging care channels could influence the industry? A5. Pharmacies offer an additional testing channel where professional services are permitted. Although they account for an estimated 1.93% revenue share in 2025, the segment is projected to grow at a CAGR of 15.93% during 2026–2032. Expansion depends on trained staff and viable reimbursement arrangements. Q6. What factors should businesses consider before entering this market? A6. Businesses need to assess test volumes and recurring consumable demand alongside equipment sales. Competitive pricing and dependable assay supply matter to laboratory customers. Distribution coverage and technical support also influence whether providers adopt a system and continue purchasing its reagents or cartridges. Q7. Where are the strongest regional growth opportunities in the market? A7. Asia-Pacific is projected to grow fastest at a CAGR of 10.15% during 2026–2032 as diagnostic access and laboratory networks expand. North America remains the largest region with an estimated 35.43% revenue share in 2025 through established testing services and reimbursement pathways. Sources: World Health Organization – Approximately 830 Million People Worldwide Were Living With Diabetes in 2022 WHO – Diabetes: Global Patient Population and Disease Burden U.S. CDC – Estimated 40.1 Million Americans Had Diabetes in 2023, Including 29.1 Million Diagnosed Individuals and 11 Million Undiagnosed Adults, While 115.2 Million Adults Had Prediabetes CDC – National Diabetes Statistics Report: Diabetes and Prediabetes Populations U.S. CDC – Recommends HbA1c Testing Every Six Months When Treatment Goals Are Met and Every Three Months Following Treatment Changes or Unmet Blood Glucose Goals CDC – Diabetes Care Schedule and Recommended HbA1c Testing Frequency U.S. Department of Health and Human Services – Medicare Part B Recorded 18,998,926 HbA1c Claim Lines and USD 181.6 Million in Spending During 2024, With Both Increasing Approximately 3% HHS Office of Inspector General – HbA1c Testing Volumes and Medicare Spending, Published January 2026 U.S. CMS – Added HbA1c to Medicare’s Diabetes-Screening Benefit From January 1, 2024, With Eligible Patients Able to Receive Up to Two Screenings Within a 12-Month Period CMS – Diabetes Screening Coverage and Frequency Update NHS England – Recorded HbA1c Measurement for 91.9% of Audited Patients With Type 2 and Other Diabetes During 2024–2025 NHS – National Diabetes Audit: Care Processes and Treatment Targets, 2024–2025 Australian Institute of Health and Welfare – As of July 2026, HbA1c Results Were Recorded Within the Previous Year for 74.9% of Regular GP Clients With Type 2 Diabetes and 60.0% With Type 1 Diabetes AIHW – HbA1c Testing Records Among General-Practice Patients With Diabetes Abbott – Launched Afinion HbA1c Dx for Afinion 2 and AS100 in June 2019, Providing Three-Minute Results to Aid Diabetes Diagnosis and Risk Assessment Abbott – Afinion HbA1c Dx Launch and Diagnostic Applications Bio-Rad Laboratories – D-100 Hemoglobin Testing System Delivers 80 Results Per Hour and Uses a 10,000-Test Analytical Column Bio-Rad – D-100 HbA1c Testing System, Throughput, and Analytical Consumables U.S. FDA – Cleared Tosoh’s HLC-723GR01 Automated Glycohemoglobin Analyzer on October 3, 2025, Under Clearance Number K250073 FDA – Tosoh GR01 HbA1c Analyzer: Regulatory Clearance Tosoh – Launched HLC-723GX2 in Japan on May 14, 2026, Targeting 2,000+ Domestic and International Sales Within Five Years Tosoh – Official HLC-723GX2 Launch Announcement and Sales Target Siemens Healthineers – DCA Vantage Produces HbA1c Results in Six Minutes From a 1 µL Whole-Blood Sample Siemens Healthineers – DCA Vantage Point-of-Care Analyzer and Clinical Testing Applications Siemens Healthineers – Atellica DCA Supports Up to Three Testing Modules With One Display and Produces HbA1c Results in Five Minutes Siemens Healthineers – Atellica DCA Analyzer: Testing Capacity and Product Availability Roche Diagnostics – cobas c 503 Provides HbA1c Testing Capacity of Up to 500 Samples Per Hour Roche – cobas c 503 Analytical Unit and HbA1c Throughput ARKRAY – ADAMS A1c HA-8190V Processes Samples in 24 Seconds in Fast Mode and 58 Seconds in Variant Mode ARKRAY – HA-8190V Automated HbA1c Analyzer and Processing Specifications EKF Diagnostics – Quo-Test Provides HbA1c Results Within Four Minutes Using a 4 µL Blood Sample for Professional Point-of-Care Monitoring EKF Diagnostics – Quo-Test HbA1c Analyzer for Diabetes Clinics and Physician Practices PTS Diagnostics – A1CNow Self Check Offers Five-Minute Home HbA1c Results Through a Four-Test Package PTS Diagnostics – A1CNow Self Check: Home Monitoring and Product Format HemoCue – HbA1c 501 Provides Results in Five Minutes Using Capillary or Venous Whole Blood HemoCue – HbA1c 501 System: Manufacturer Product Specifications U.S. FDA – Cleared Lifotronic’s H100Plus Hemoglobin Testing System on October 2, 2026, Under Clearance Number K260468 FDA – H100Plus Hemoglobin Testing System: Regulatory Clearance Lifotronic – H100Plus Receives U.S. FDA Clearance Siemens Healthineers – Announced 24 CE-Marked Capillary Testing Claims, Including HbA1c, for Atellica Laboratory Analyzers on July 23, 2026 Siemens Healthineers – Expanded Capillary Testing Claims for Atellica Analyzers U.S. FDA – Listed 24,077 Atellica Enzymatic HbA1c Assay-Product Units in a June 2026 Correction Concerning Potentially Elevated or Depressed Results FDA – Siemens Atellica CH Enzymatic Hemoglobin A1c Recall, Z-2703-2026 Table of Contents - Global HbA1c Testing Devices Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Product, Testing Setting, Technology, Application, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Product, Testing Setting, Technology, Application, End User, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Product, Testing Setting, Technology, Application, and End User Consumables and Instrument Revenue Positioning Laboratory Testing and Professional Point-of-Care Testing Market Positioning Investment Opportunities in the HbA1c Testing Devices Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Reagents, Consumables, Home-Testing Kits, and Professional Point-of-Care Testing Investment Opportunities in Enzymatic Methods, Prediabetes Monitoring, and Pharmacy-Based Testing Services Commercial Opportunities in Laboratory Modernization and Multipurpose Clinical Chemistry Platforms Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of HbA1c Testing in Diabetes Monitoring, Diabetes Screening and Diagnosis, and Prediabetes Monitoring Role of Laboratory Testing, Professional Point-of-Care Testing, and Home-Use Testing in Diabetes Care Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory and Public Health Factors Role of Recurring Diabetes Monitoring and Screening Reimbursement in Market Expansion Impact of Reagent and Cartridge Consumption on Recurring Market Revenue Point-of-Care Testing Adoption and Expansion of Clinical Testing Access Laboratory Quality Requirements, Assay Reliability, and Regulatory Compliance Trends Impact of Capillary Sample Collection and Multipurpose Laboratory Platforms Global HbA1c Testing Devices Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product: Reagents, Consumables and Home-Testing Kits Instruments Market Analysis by Testing Setting: Laboratory Testing Professional Point-of-Care Testing Home-Use Testing Market Analysis by Technology: Ion-Exchange Chromatography Immunoassay Boronate-Affinity Methods Enzymatic Methods Capillary Electrophoresis Other Methods Market Analysis by Application: Diabetes Monitoring Diabetes Screening and Diagnosis Prediabetes Monitoring Market Analysis by End User: Hospitals Independent Diagnostic Laboratories Primary Care and Community Health Centers Diabetes and Endocrinology Clinics Home Users Pharmacies Other End Users Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East and Africa Regional Market Analysis North America HbA1c Testing Devices Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product, Testing Setting, Technology, Application, and End User Country-Level Breakdown: United States Canada Europe HbA1c Testing Devices Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product, Testing Setting, Technology, Application, and End User Country-Level Breakdown: United Kingdom Germany France Italy Rest of Europe Asia-Pacific HbA1c Testing Devices Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product, Testing Setting, Technology, Application, and End User Country-Level Breakdown: China Japan South Korea India Australia Rest of Asia-Pacific Latin America HbA1c Testing Devices Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product, Testing Setting, Technology, Application, and End User Country-Level Breakdown: Brazil Mexico Rest of Latin America Middle East and Africa HbA1c Testing Devices Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product, Testing Setting, Technology, Application, and End User Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East and Africa Competitive Intelligence and Benchmarking Leading Key Players: Bio-Rad Laboratories Tosoh Bioscience Abbott Roche Diagnostics Siemens Healthineers ARKRAY EKF Diagnostics PTS Diagnostics HemoCue Lifotronic Beckman Coulter Danaher Corporation Nova Biomedical Randox Laboratories Competitive Landscape and Strategic Insights Benchmarking Based on Assay Performance, Analyzer Capacity, Testing Speed, Consumable Availability, and Regional Presence Supplier Qualification and Regulatory Compliance Capability Analysis Laboratory Analyzer and Consumables Portfolio Positioning Professional Point-of-Care and Home-Testing Product Positioning Reagent, Cartridge, Analytical Column, and Assay Supply Strategy Analysis Product Quality, Technical Support, and Laboratory Customer Retention Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Segmentation by Product, Testing Setting, Technology, Application, End User, and Region (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Country-Level Market Assessment Across North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa Competitive Benchmarking of Leading HbA1c Testing Devices Manufacturers Laboratory Testing and Professional Point-of-Care Testing Comparison Technology Adoption Trends Across Ion-Exchange Chromatography, Immunoassay, Boronate-Affinity Methods, Enzymatic Methods, and Capillary Electrophoresis Consumables, Instruments, and Home-Testing Kits Product Portfolio Analysis Regulatory Developments and Product Launches During 2025 and 2026 List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Market Share by Product, Testing Setting, Technology, Application, and End User (2025 vs. 2032) Growth Strategies Adopted by Key Players Market Structure by Product and Testing Setting Technology Adoption Across Laboratory and Point-of-Care Testing Global HbA1c Testing Devices Ecosystem and Value Chain Analysis